Pharmac is proposing to fund drugs for breast cancer, lung cancer and multiple sclerosis from December 1.New Zealand's Cancer Society welcomes Pharmac's announcement this afternoon that breast cancer drug TDM-1 Kadcyla and lung cancer drug Alectinib (known commercially as Alecensa) will be funded.Its Medical Director Dr Chris Jackson tells Karyn Hay this positive step creates fairer access to cancer treatment in New Zealand, but Pharmac must speed up its processes.
Dr Chris Jackson, Medical Director, Cancer Society of New Zealand Photo: Cancer Society of New Zealand
